Treatment Action Group (TAG) released a publication exploring the role of community engagement in health-related research and development (R&D), particularly within the Unitaid-funded LONGEVITY Project. LONGEVITY, led by the University of Liverpool and whose consortium members include TAG, aims to develop long-acting technologies (LATs) to prevent TB and malaria, and to cure hepatitis C virus (HCV).
To ensure that any eventual LATs benefit the communities that need them, TAG and Afrocab created the Long-Acting Technologies Community Advisory Board (LAT CAB,) a network of research literate survivors, civil society members, clinicians, and activists who advocate for affected community priorities at every step of the R&D, implementation, and policymaking process.
To illustrate LAT CAB’s key role, the publication included excerpts from their communications with various global health actors.
Download the publication below.